August 4, 2025

Figure S2 from A RAS(ON) Multi-Selective Inhibitor Combination Therapy Triggers Long-term Tumor Control through Senescence-Associated Tumor-Immune Equilibrium in Pancreatic Ductal Adenocarcinoma

View Full Paper

Ask AI

Bookmark

MAIN FINDING: Multi-selective inhibitor combination therapy triggers long-term tumor control in pancreatic ductal adenocarcinoma.
KEY EVIDENCE: The therapy does not enhance RAS inhibitor-driven cell death, nor does it affect phospho ERK inhibition.
APPROACH: The study employs a combination therapy approach to target RAS pathways involved in tumor progression.
SIGNIFICANCE: This research highlights the importance of tumor-immune equilibrium for effective cancer treatment strategies.

Implication

Combination therapy shows durable tumor control in pancreatic ductal adenocarcinoma, suggesting a role of tumor-immune equilibrium.

Palbociclib does not increase RASi-driven cell death or affect RASi-driven phospho ERK inhibition

No takes yet. Share an insight, caveat, or question.

Broderick et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

Combination therapy shows durable tumor control in pancreatic ductal adenocarcinoma, suggesting a role of tumor-immune equilibrium.

Palbociclib does not increase RASi-driven cell death or affect RASi-driven phospho ERK inhibition